The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice-Reference-Cited by-同舟云学术

The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice

Published:2023-01 Issue:1 Volume:4 Page:100893
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Ullah Irfan,Beaudoin-Bussières Guillaume,Symmes Kelly,Cloutier Marc,Ducas Eric,Tauzin Alexandra,Laumaea Annemarie,Grunst Michael W.,Dionne Katrina,Richard Jonathan,Bégin Philippe,Mothes Walther,Kumar Priti,Bazin Renée,Finzi Andrés,Uchil Pradeep D.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference66 articles.

1. Return to the past: the case for antibody-based therapies in infectious diseases;Casadevall;Clin. Infect. Dis.,1995

2. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis;Mair-Jenkins;J. Infect. Dis.,2015

3. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?;Luke;Ann. Intern. Med.,2006

4. Convalescent plasma: possible therapy for novel coronavirus disease 2019;Cao;Transfusion,2020

5. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients;Beraud;Transfus. Apher. Sci.,2022

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults;Immunity & Ageing;2024-09-14

2. Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice;Vaccines;2024-09-02

3. Protective non-neutralizing SARS-CoV-2 monoclonal antibodies;Trends in Immunology;2024-08

4. Deciphering Fc-effector functions against SARS-CoV-2;Trends in Microbiology;2024-08

5. Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence;The Journal of Immunology;2024-07-17